IGF1R and bone sarcoma: In 2011, Fleuren et al. published a study based on the previsouly formulated 111In-R1507 119, a radiolabeled antibody against insulin-like growth factor 1 receptor (IGF-1R), and tested if 111In-R1507 is a predictive marker for response by bone sarcoma patients to anti-IGF-1R therapy.